Similarly, Gojo et al. showed that the association of the PD1 inhibitor pembrolizumab with AZA led to promising results in terms of response rates in R/R AML patients, with greater clinical activity in newly diagnosed, older AML patients [46]. Here, PDCD1 is linked to acute myeloid leukemia.